Advances in complement-targeted therapeutics have been particularly striking in diseases such as myasthenia gravis (MG) and aquaporin-4 IgG-positive neuromyelitis optica spectrum disorder (AQP4 + NMOSD). This evidence concerns the gene AQP4 and myasthenia gravis.